Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung ...

Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

LOS ANGELES, July 15, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...

South Korea’s Samsung Bioepis today announced it has entered into a license, development and commercialization agreement (DCA ...

Harrow is a strong swing trade in the $20s, with long-term upside as sales and new product launches drive sustained profits.

Harrow (NASDAQ:HROW) stock gains as Cantor Fitzgerald gives an Overweight rating for the company, citing a conservative outlook. Read more here.

Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised ...

Our tireless food critics and writers went into the tagliatelle trenches, emerging with a list of Greater Boston’s very best ...

We feel now is a pretty good time to analyse Harrow, Inc.'s (NASDAQ:HROW) business as it appears the company may be on the cusp of a considerable accomplishment. Harrow, Inc., an eyecare ...